182 related articles for article (PubMed ID: 36917693)
1. Treatment of Prostate Cancer with CD46-targeted 225Ac Alpha Particle Radioimmunotherapy.
Bidkar AP; Wang S; Bobba KN; Chan E; Bidlingmaier S; Egusa EA; Peter R; Ali U; Meher N; Wadhwa A; Dhrona S; Dasari C; Beckford-Vera D; Su Y; Tang R; Zhang L; He J; Wilson DM; Aggarwal R; VanBrocklin HF; Seo Y; Chou J; Liu B; Flavell RR
Clin Cancer Res; 2023 May; 29(10):1916-1928. PubMed ID: 36917693
[TBL] [Abstract][Full Text] [Related]
2. CD46-Targeted Theranostics for PET and 225Ac-Radiopharmaceutical Therapy of Multiple Myeloma.
Wadhwa A; Wang S; Patiño-Escobar B; Bidkar AP; Bobba KN; Chan E; Meher N; Bidlingmaier S; Su Y; Dhrona S; Geng H; Sarin V; VanBrocklin HF; Wilson DM; He J; Zhang L; Steri V; Wong SW; Martin TG; Seo Y; Liu B; Wiita AP; Flavell RR
Clin Cancer Res; 2024 Mar; 30(5):1009-1021. PubMed ID: 38109209
[TBL] [Abstract][Full Text] [Related]
3. Development of CD46 targeted alpha theranostics in prostate cancer using
Bobba KN; Bidkar AP; Wadhwa A; Meher N; Drona S; Sorlin AM; Bidlingmaier S; Zhang L; Wilson DM; Chan E; Greenland NY; Aggarwal R; VanBrocklin HF; He J; Chou J; Seo Y; Liu B; Flavell RR
Theranostics; 2024; 14(4):1344-1360. PubMed ID: 38389832
[No Abstract] [Full Text] [Related]
4. Molecular Imaging of Prostate Cancer Targeting CD46 Using ImmunoPET.
Wang S; Li J; Hua J; Su Y; Beckford-Vera DR; Zhao W; Jayaraman M; Huynh TL; Zhao N; Wang YH; Huang Y; Qin F; Shen S; Gioeli D; Dreicer R; Sriram R; Egusa EA; Chou J; Feng FY; Aggarwal R; Evans MJ; Seo Y; Liu B; Flavell RR; He J
Clin Cancer Res; 2021 Mar; 27(5):1305-1315. PubMed ID: 33293372
[TBL] [Abstract][Full Text] [Related]
5. CD46 targeted
Li J; Huang T; Hua J; Wang Q; Su Y; Chen P; Bidlingmaier S; Li A; Xie Z; Bidkar AP; Shen S; Shi W; Seo Y; Flavell RR; Gioeli D; Dreicer R; Li H; Liu B; He J
J Exp Clin Cancer Res; 2023 Mar; 42(1):61. PubMed ID: 36906664
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of
Bobba KN; Bidkar AP; Meher N; Fong C; Wadhwa A; Dhrona S; Sorlin A; Bidlingmaier S; Shuere B; He J; Wilson DM; Liu B; Seo Y; VanBrocklin HF; Flavell RR
J Nucl Med; 2023 Jul; 64(7):1076-1082. PubMed ID: 37201957
[No Abstract] [Full Text] [Related]
7. Radioimmunotherapy of breast cancer metastases with alpha-particle emitter 225Ac: comparing efficacy with 213Bi and 90Y.
Song H; Hobbs RF; Vajravelu R; Huso DL; Esaias C; Apostolidis C; Morgenstern A; Sgouros G
Cancer Res; 2009 Dec; 69(23):8941-8. PubMed ID: 19920193
[TBL] [Abstract][Full Text] [Related]
8. Actinium-225 conjugates of MAb CC49 and humanized delta CH2CC49.
Kennel SJ; Brechbiel MW; Milenic DE; Schlom J; Mirzadeh S
Cancer Biother Radiopharm; 2002 Apr; 17(2):219-31. PubMed ID: 12030116
[TBL] [Abstract][Full Text] [Related]
9. Preclinical efficacy of a PSMA-targeted actinium-225 conjugate (225Ac-macropa-pelgifatamab) - a targeted alpha therapy for prostate cancer.
Schatz CA; Zitzmann-Kolbe S; Moen I; Klotz M; Nair S; Stargard S; Bjerke RM; Wickstrøm Biseth K; Feng YZ; Indrevoll B; Cruciani V; Karlsson J; Haendler B; Nielsen CH; Alfsen MZ; Hammer S; Hennekes H; Cuthbertson A; Hagemann UB; Larsen A
Clin Cancer Res; 2024 Apr; ():. PubMed ID: 38593212
[TBL] [Abstract][Full Text] [Related]
10. Alpha radioimmunotherapy using
Cheal SM; McDevitt MR; Santich BH; Patel M; Yang G; Fung EK; Veach DR; Bell M; Ahad A; Vargas DB; Punzalan B; Pillarsetty NVK; Xu H; Guo HF; Monette S; Michel AO; Piersigilli A; Scheinberg DA; Ouerfelli O; Cheung NV; Larson SM
Theranostics; 2020; 10(25):11359-11375. PubMed ID: 33052220
[TBL] [Abstract][Full Text] [Related]
11. Clinical Studies with Bismuth-213 and Actinium-225 for Hematologic Malignancies.
Jurcic JG
Curr Radiopharm; 2018; 11(3):192-199. PubMed ID: 29793418
[TBL] [Abstract][Full Text] [Related]
12. Efficient 1-step radiolabeling of monoclonal antibodies to high specific activity with 225Ac for α-particle radioimmunotherapy of cancer.
Maguire WF; McDevitt MR; Smith-Jones PM; Scheinberg DA
J Nucl Med; 2014 Sep; 55(9):1492-8. PubMed ID: 24982438
[TBL] [Abstract][Full Text] [Related]
13. Preclinical Evaluation of 225Ac-Labeled Single-Domain Antibody for the Treatment of HER2pos Cancer.
Rodak M; Dekempeneer Y; Wojewódzka M; Caveliers V; Covens P; Miller BW; Sevenois MB; Bruchertseifer F; Morgenstern A; Lahoutte T; D'Huyvetter M; Pruszyński M
Mol Cancer Ther; 2022 Dec; 21(12):1835-1845. PubMed ID: 36129807
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of 225Ac for vascular targeted radioimmunotherapy of lung tumors.
Kennel SJ; Chappell LL; Dadachova K; Brechbiel MW; Lankford TK; Davis IA; Stabin M; Mirzadeh S
Cancer Biother Radiopharm; 2000 Jun; 15(3):235-44. PubMed ID: 10941530
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic efficacy and toxicity of 225Ac-labelled vs. 213Bi-labelled tumour-homing peptides in a preclinical mouse model of peritoneal carcinomatosis.
Essler M; Gärtner FC; Neff F; Blechert B; Senekowitsch-Schmidtke R; Bruchertseifer F; Morgenstern A; Seidl C
Eur J Nucl Med Mol Imaging; 2012 Apr; 39(4):602-12. PubMed ID: 22237842
[TBL] [Abstract][Full Text] [Related]
16. An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer.
McDevitt MR; Barendswaard E; Ma D; Lai L; Curcio MJ; Sgouros G; Ballangrud AM; Yang WH; Finn RD; Pellegrini V; Geerlings MW; Lee M; Brechbiel MW; Bander NH; Cordon-Cardo C; Scheinberg DA
Cancer Res; 2000 Nov; 60(21):6095-100. PubMed ID: 11085533
[TBL] [Abstract][Full Text] [Related]
17.
Pfannkuchen N; Bausbacher N; Pektor S; Miederer M; Rosch F
Curr Radiopharm; 2018; 11(3):223-230. PubMed ID: 29866026
[TBL] [Abstract][Full Text] [Related]
18. An Overview of Targeted Alpha Therapy with
Morgenstern A; Apostolidis C; Kratochwil C; Sathekge M; Krolicki L; Bruchertseifer F
Curr Radiopharm; 2018; 11(3):200-208. PubMed ID: 29732998
[TBL] [Abstract][Full Text] [Related]
19. Breakthrough of 225Ac and its radionuclide daughters from an 225Ac/213Bi generator: development of new methods, quantitative characterization, and implications for clinical use.
Ma D; McDevitt MR; Finn RD; Scheinberg DA
Appl Radiat Isot; 2001 Nov; 55(5):667-78. PubMed ID: 11573800
[TBL] [Abstract][Full Text] [Related]
20. The feasibility of 225Ac as a source of alpha-particles in radioimmunotherapy.
Geerlings MW; Kaspersen FM; Apostolidis C; van der Hout R
Nucl Med Commun; 1993 Feb; 14(2):121-5. PubMed ID: 8429990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]